Valeo Financial Advisors’s VanEck Biotech ETF BBH Stock Holding History

Valeo Financial Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10	Closed	-$1K	–	2027
2020 Q1	$1K	Hold	10	–	–	﹤0.01%	1624
2019 Q4	$1K	Hold	10	–	–	﹤0.01%	1516
2019 Q3	$1K	Buy	+10	New	+$1.24K	﹤0.01%	1438

Other funds holding BBH

PAG

Pinnacle Advisory Group Columbia, Maryland $2.17B AUM 39.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Valeo Financial Advisors's BBH Position: Q2 2020 in Review

Valeo Financial Advisors sold out of VanEck Biotech ETF (BBH) in Q2 2020, closing a stake of 10 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in BBH in Q3 2019 and held it in 3 quarters. The position peaked at $1K in Q1 2020. 102 funds tracked by Wall St. Rank hold BBH as of Q2 2020.

Valeo Financial Advisors reported no remaining VanEck Biotech ETF position as of Q2 2020 after selling out during the quarter.
Valeo Financial Advisors sold 10 VanEck Biotech ETF shares in Q2 2020, an estimated $1K.
Valeo Financial Advisors first reported a position in VanEck Biotech ETF in Q3 2019 and held it in 3 quarters.
Valeo Financial Advisors's VanEck Biotech ETF position peaked at $1K in Q1 2020.
102 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2020.

Based on Valeo Financial Advisors's 13F filing for Q2 2020, filed 20 Jul 2020.